Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119416) titled 'Study on the efficacy and safety of Lukang saltuzumab +/- bevacizumab in the population with TROP2 highly expressed peritoneal metastatic cance' on Feb. 26.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Beijing luhe hospital Affiliated to Capital Medical University
Condition:
peritoneal metastatic carcinoma
Intervention:
Group A:Lukang saltuzumab + bevacizumab
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-02-26
Target Sample Size: Group A:10;Group B:10;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj...